Futura Medical plc ("Futura") develops
innovative products for the consumer
healthcare market.
Our vision is to leverage our skills and expertise to bring to market
some of the worlds most innovative consumer healthcare products.
The Companys strategy is to out-license manufacture and distribution
to major pharmaceutical and healthcare groups.
Futura is developing a portfolio of products in sexual healthcare
and pain relief management and is evaluating further therapeutic
opportunities as potential additions to its growing pipeline.
Futura is based at The Surrey Research Park, Guildford, Surrey, and
its shares trade on the AIM market of the London Stock Exchange.
Our business strategy is centred on selecting and
developing products based on five key criteria:
Return on Investment: we focus on consumer
healthcare products that offer the potential for a
significant return on the costs of development.
Product Profile: we focus on locally applied
medicines, either stand-alone or in combination with
a medical device. We only use existing chemical
entities which enables us to have a lower risk profile.
Over The Counter ("OTC"): our aim is to produce
safe and effective OTC products made available
to consumers on a general retail basis or through
chemists without the need for a doctors prescription.
Strong Intellectual Property: the products
are underpinned by our developing and
retaining valuable intellectual property including
know-how, patents and trademarks to protect
their commercial position.
Licensing: we aim to license our products
during their development to established
pharmaceutical and healthcare groups
who offer the best potential commercial
opportunities.
